Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 11/20 | 0.45 |
| ▸ | FABP4 | P15090 | 3/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31198407 | 1.00 | ACLY (0.45) | ACLYFABP4FABP5PTK2BSMN1; SMN2 | |
| SCHEMBL24928654 | 0.90 | ACLY (0.37) | ACLYFABP4PTK2BSMN1; SMN2TDP1 | |
| SCHEMBL31198454 | 0.90 | ACLY (0.37) | ACLYFABP4PTK2BSMN1; SMN2TDP1 | |
| SCHEMBL24928715 | 0.89 | ACLY (0.37) | ACLYFABP4PTK2BSMN1; SMN2TDP1 | |
| SCHEMBL30153301 | 0.89 | ACLY (0.37) | ACLYFABP4PTK2BSMN1; SMN2TDP1 | |
| SCHEMBL24928649 | 0.86 | ACLY (0.41) | ACLYFABP4FABP5ERAP1TDP1 | |
| SCHEMBL30153363 | 0.86 | ACLY (0.41) | ACLYFABP4FABP5ERAP1TDP1 | |
| SCHEMBL30153205 | 0.83 | ACLY (0.35) | ACLYFABP4PTK2BSMN1; SMN2TDP1 | |
| SCHEMBL24928721 | 0.83 | ACLY (0.35) | ACLYFABP4PTK2BSMN1; SMN2TDP1 | |
| SCHEMBL22637065 | 0.81 | ACLY (0.41) | ACLYPTK2BSMN1; SMN2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023007188-A1 | PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2023-02-02 | — | — | WO | disclosed |